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 ?dĂŬĞŚŽŵĞ ?ŵĞƐƐĂŐĞ ?DŝŐƌĂƚŝŽn is a key driver of tuberculosis (TB) in many low incidence settings. 
Our method combines global TB infection estimates with migration data to provide useful insights 
into the prevalence of latent TB in a low-incidence setting, Australia. 
  
Summary 
Migration is a key driver of tuberculosis (TB) in many low incidence settings, with the majority of TB 
cases attributed to reactivation of latent TB (LTBI) acquired overseas. A greater understanding of LTBI 
risk in heterogeneous migrant populations would aid health planning. We aimed to estimate the LTBI 
prevalence and distribution among local and overseas-born Australians. 
Annual risks of tuberculosis infection estimates were applied to population cohorts (by country of birth, 
year of arrival and age) in Australian census data in 2006, 2011 and 2016. 
Both the absolute number and proportion of Australian residents with LTBI increased  ? from 4.6% (IQR 
[interquartile range] 4.2-5.2%) in 2006 to 5.1% (IQR 4.7%-5.5%) in 2016  ? due to the increasing 
proportion of the population born overseas (23.8% in 2006 to 28.3% in 2016). Of all residents estimated 
to have LTBI in 2016; 93.2% were overseas born, 21.6% were <35 years of age and 34.4% had migrated 
to Australia since 2007. 
The overall prevalence of LTBI in Australia is low. Some residents, particularly migrants from high 
incidence settings, may have considerably higher risk of LTBI, and these findings allow for tailored public 
health interventions to reduce the risk and impact of future TB disease.  
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Introduction  
In many low-incidence settings, most TB cases now occur among residents born in high-incidence 
countries and are attributed to reactivation of latent TB (LTBI) acquired overseas.
1
 LTBI is asymptomatic 
and not infectious, but those with LTBI can be treated to reduce their future risk of reactivation TB,
2
 and 
several low-incidence countries are now considering, or have implemented, screening and treatment for 
LTBI among high-risk recent immigrants.
3
 It is essential that any strategy is well targetted to those at 
highest risk of active TB to ensure a favourable risk/benefit ratio for both society and individuals.
4
 
5
 
However, migrant populations can be very heterogeneous with regards to source country, age and time 
since migration, and most LTBI prevalence studies in migrant populations are limited to opportunistically 
selected groups with identifiable risk factors and demographic profiles that are unlikely to be 
generalisable to the entire migrant cohorts.
6
  
In 2016, Houben and Dodd estimated the prevalence of global LTBI by estimating trends in annual risk of 
infection (ARTI) for 168 countries from 1934 to 2014.
7
 In Australia, as in many low-incidence settings, 
immigration is a key driver of the burden of LTBI and rich data exist on immigration by country of origin, 
age and year. Therefore, the potential exists to combine estimated TB infection rates with domestic 
census data to quantify the LTBI burden and understand the effects of immigration.  
We aimed to estimate the prevalence of LTBI in Australia, to describe its evolution over time and 
identify populations at greatest risk of infection. This is an important first step in identifying those 
populations that are at the highest risk of TB reactivation, and will inform future effective public health 
interventions towards TB elimination. 
 
Methods 
Australian census data 
Australian population data from the 2006, 2011 and 2016 censuses were exported from the Australian 
Bureau of Statistics (ABS) Table Builder
8
 by country of birth, age, year of arrival, State/Territory of 
residence and residence within ^ƚĂƚĞ ?dĞƌƌŝƚŽƌǇ ?ƐĐĂƉŝƚĂůĐŝƚǇ.  
Residents ĐĂƚĞŐŽƌŝƐĞĚĂƐ “ŶŽƚƐƚĂƚĞĚ ? ? “ŝŶĂĚĞƋƵĂƚĞůǇĚĞƐĐƌŝďĞĚ ? ? “ŽǀĞƌƐĞĂƐǀŝƐŝƚŽƌ ? Žƌ “ĂƚƐĞĂ ?in the 
census country of birth or year of arrival categories were excluded from analysis.
9
  
Annual risk of infection 
The methods used by Houben and Dodd 2016 to construct trends in annual risk of infection (ARTI) for 
168 countries from 1934 to 2014 have been described in detail previously.
7
 Briefly, for each country and 
for each year, 200 simulated ARTI trajectories were estimated using data from tuberculin skin test (TST) 
surveys, with sample size and mean age used to quantify uncertainty. Where TST surveys were 
unavailable, estimates of  ARTI were obtained using a revised Styblo ratio that accounts for 
uncertainty.
10
 The Styblo ratio relates the annual risk of infection and prevalence of smear-positive 
tuberculosis.
11 12
 The prevalence of smear-positive TB was estimated using WHO Global TB Programme 
prevalence estimates (1990 ?2014)13 and incorporating WHO assumptions regarding case detection rates 
and disease duration by HIV-status, as well as assumptions regarding the fraction of smear-positive 
disease by HIV status
14
 and age-group.
15
  
To increase precision for the six most common countries of birth in Australia (Australia, the United 
Kingdom, China, Vietnam, India and the Philippines), we simulated 5000 ARTI trajectories. To reflect 
characteristics relevant to transmission in Australia, the proportion of TB cases that were smear-positive 
was set to 21.5% based on the Australian average proportion from 2008 to 2013.
1 16-18
  The ARTI 
estimate for 2014 was also applied to the years 2015 and 2016.  
The risk of infection for each population cohort (by country of birth, age and year of arrival if overseas-
born) in each census dataset was calculated by summing the relevant hazards (FOI=force of infection) 
for each year of residency in Australia and birth country (for overseas-born residents). To account for 
variation in birth dates and dates of migration across years (which were unknown), the hazards in birth 
years were halved, and in years of migration half the hazard for each of the birth country and Australia 
was used. This assumes that the average time of birth or migration of the cohort was the mid-point of 
the year of birth or migration. Hazards in census years were apportioned based on the census date. The 
total risk of infection (R) for each population group was then calculated as one minus the exponential of 
the cumulative FOIs experienced: ܴ ൌ  ? െ ݁ ?ିሺ஺௟௟ிைூ௦ሻ where FOI=force of infection  
A full mathematical description of this method appears in the Appendices.  
 Ethics statement 
Approval from a Human Research Ethics Committee was not required under the rules of our institutions. 
  
RESULTS 
LTBI in Australia 
The number of Australians estimated to have LTBI increased over time from approximately 838,000 (IQR 
[interquartile range] 764,000-950,000) in 2006 to 1,084,000 (IQR 1,017,000-1,172,000) in 2016, with the 
percentage of Australians estimated to have LTBI increasing from 4.6% (IQR 4.2%-5.2%) in 2006 to 5.1% 
(IQR 4.7%-5.5%) in 2016 (Figure 1). Our results are estimates based on a Bayesian approach, and so 
computing P-values for comparisons between years was not appropriate, but the uncertainty intervals 
suggest no strong evidence of a trend. 
Considering the Australian-born and overseas-born groups separately, the estimated LTBI percentages in 
the Australian-born residents were comparable in 2006 and 2016 (0.4% [IQR 0.3-0.9%] and 0.4% [IQR 
0.3-0.7%]) and the percentage of overseas-born residents infected also changed little from 18.0% (IQR 
16.7-19.6%) to 17.1% (IQR 16.2-18.1%). The reason why the proportions in the Australian-born and 
overseas-born subgroups changed little over time while there was a simultaneous increase in the 
proportion of all Australians estimated to have LTBI was because of the increasing proportion of the 
Australian population who were born overseas during the study years (23.8% in 2006 to 28.3% in 2016). 
The number of overseas-born residents estimated to have LTBI increased from 756,000 (IQR 699,000-
822,000) in 2006 to 998,000 (IQR 943,000-1,058,000) in 2016. 
With declining ARTI estimates in many countries worldwide, the percentage estimated to have LTBI 
increased with age in both Australian-born and overseas-born populations (Figure 2). Due to the age 
distribution of the populations (not shown) the largest number estimated to have LTBI were in the 35-64 
year age-groups (Figure 2).  
  
Among overseas-born residents, the number of persons with LTBI increased from 2006 to 2016 in all age 
groups, with the largest absolute increase in the 35-64 year and 15-34 year age groups, and percentage 
increases of 37.7%, 69.4%, 25.4% and 26.6% in the 0-14, 15-34, 35-64 and 65+ age groups respectively 
(Figure 2). The proportion of overseas-born residents estimated to have LTBI appeared to decrease 
marginally over time in all age-groups, except in the 35-64 year group, in which it changed little from 
19.5% (IQR 17.9%-21.1%) in 2006 to 20.1% (IQR 18.7%-21.3%) in 2016 (Figure 2).  
The average age of residents with LTBI appeared to decrease slightly from 51.9 years in 2006 to 50.7 
years in 2016; increasing in the Australian-born population (50.5 years in 2006 to 52.4 years in 2016) and 
decreasing in the overseas-born (52.0 years in 2006 to 50.6 years in 2016). The percentage of residents 
with LTBI under the age of 35 years increased from 17.4% in 2006 to 21.6% in 2016.  
Overseas-born residents 
In 2016, over 6.1 million Australian residents were born overseas in over 190 countries, constituting 
28.3% of the Australian population. The increasing numbers of Australians born in high burden 
countries
19
 over time is illustrated in Figure 3. Australian residents born in India, China, the Philippines 
and Vietnam made up the greatest number estimated to have LTBI in 2016; with the prevalence varying 
by age (Table 1 and Figure 4). 
Overseas-born residents arriving 2007-2016 
An estimated 15.4% of migrants arriving from 2007 until the census in 2016 had LTBI on arrival, with this 
group contributing 34.4% of all LTBI in Australia in 2016 and new migrants aged under 35 years 
contributing 16.3%.  
Spatial distribution  
The majority of persons with LTBI resided in major urban centres, particularly Greater Sydney and 
Greater Melbourne (Figure S1). LTBI prevalence increased in all regions from 2006 to 2016, most notably 
in the Northern Territory (1.7% in 2006 to 3.3% in 2016), Greater Perth (3.8 to 4.9%) and the Australian 
Capital Territory (2.8 to 3.9%). It is also possible to identify where those at greatest risk of TB infection 
live in urban areas, if census data provides this level of spatial detail (Figure S1).  
Missing data 
The percentage missing country of birth and/or year of arrival information in the 2006, 2011 and 2016 
census data was 8.0%, 6.7% and 9.15% respectively. These census ƌĞƐƉŽŶĚĞŶƚƐǁĞƌĞĐĂƚĞŐŽƌŝƐĞĚĂƐ “ŶŽƚ
ƐƚĂƚĞĚ ? and for a significant percentage (~70-80% depending on the year) the answers to most other 
ĐĞŶƐƵƐƋƵĞƐƚŝŽŶƐǁĞƌĞƐŝŵŝůĂƌůǇ “ŶŽƚƐƚĂƚĞĚ ?, suggesting they had been imputed by the ABS to account 
for non-responding dwellings.
9 20 21
 The ABS post-enumeration survey data in the census years estimated 
the majority of non-responders to be Australian-born (e.g. 84.8% in 2016, which was calculated using 
the Tablebuilder census count and published net undercount rate of 8.1%).
9 20 21
 and countries of birth of 
other non-responders were similarly distributed to census respondents in 2016.  
DISCUSSION 
Our method provided useful insights into the prevalence of LTBI in Australia; a low-incidence setting 
with high levels of migration. Both the prevalence and total number of people with LTBI in Australia rose 
from 2006 to 2016, with the highest proportions seen in major metropolitan areas. The increasing 
prevalence of LTBI can be attributed to increasing numbers of overseas-born residents from countries 
with a high burden of TB such as India, China and the Philippines. New arrivals were predominantly 
young adults and families, such that an increasing proportion of those estimated to have LTBI during the 
study period were under 35 years of age. During this time, we found that around 15% of migrants to 
Australia had LTBI. However, due to high levels of migration from high-burden countries since the 1980s, 
the majority of those estimated to have LTBI in Australia in 2016 were over 35 years of age.   
Our study highlighted that despite the increasing prevalence of LTBI in Australia, the prevalence is low 
(5.1% in 2016) and far lower than the estimated global burden of 23% in 2014.
7
 Moreover, the 
proportion of residents estimated to have LTBI in the overseas-born population appeared to fall over 
time, due to the declining incidence of TB in the countries where most overseas-born residents were 
born (for example, India, and China).
19
 How the prevalence of LTBI in Australia, and other similar low-
incidence settings, change in the future will be influenced by rates of migration, age at migration, source 
countries, and how TB incidence in those source countries changes over time, in addition to the 
implementation and effectiveness of any additional TB control strategies locally. 
Looking to the future, the addition of LTBI screening and treatment could be considered for migrant 
groups in Australia, as is done in several other low-incidence countries.
22
 LTBI treatment is commonly 
limited to those aged under 35 years because the frequency of adverse effects increases with age,
23
 
24
 
although recent research has shown that shorter LTBI treatment regimens containing rifampicin have a 
significantly lower risk of hepatotoxicity, so recommendations for testing older age groups may expand 
into the future.
25
 Our approach is able to quantify LTBI burden in sub-populations from low-burden 
countries, ensuring improved estimates of the pre-test probability of LTBI essential for predicting the 
efficiency of any proposed screening program. In addition, understanding LTBI distribution is helpful 
even where preventive therapy would not be indicated, and allows alternative interventions (such as 
community and healthcare worker education about TB disease) to be optimised. Migrants arriving from  
high-burden settings from 2007 to 2016 made up over 30% of all those with LTBI in Australia in 2016, 
and because recently arriving migrants are at higher risk of reactivating than those that have settled in 
Australia for longer 
26
 screening and treating this group may be beneficial. Quantifying this benefit will 
be a focus of future work,  which will incorporate estimation of TB reactivation rates among sub-
populations with LTBI. Given the significant uncertainty around rates of LTBI reactivation
27
 this work will 
be beneficial in predicting the benefit of screening and treatment strategies in our setting.   
In low incidence settings, where national TST prevalence surveys have long been abandoned and the 
majority of cases occur among overseas-born residents, indirect LTBI estimates based on modelled 
annual risks of infection in countries of birth combined with migration data are a natural approach. Our 
analysis incorporates both TB incidence in countries-of-birth and age, both of which have been shown to 
be independently associated with the prevalence of LTBI among migrants in the international literature.
6 
28 29
 Limitations of our approach include that applying a constant ARTI for all residents of a particular 
country in a particular year obscures individual variation in risk within populations due to a range of risk 
factors, such as immunological status.
30
  
Migrants who move from a high TB-burden setting to a low-incidence setting may do so for many 
different reasons and may not be representative (demographically or socioeconomically) of individuals 
of the same age in their country of origin,
31
 which may influence their risk of having been infected. Most 
LTBI prevalence studies, including those in Australia,
32-34
 exclusively consider refugee populations; which 
are often screened due to a  perception of higher risk.
35
 Previously published LTBI prevalence in these 
populations do exceed our estimates (data not shown),
32-34
 however, humanitarian entrants made up 
only 2-3% of all migrants to Australia from 2006-2016, and we consider this unlikely to substantially 
impact our estimates presented here.
36
 Further, we note that several international studies in migrant 
cohorts have resulted in similar estimates to those using our method. LTBI prevalence estimates in the 
entire US migrant population were provided by Shea et al. 2014 using results from the 1999-2000 
National Health and Nutrition Examination Survey, and they reported that 18.7% of overseas-born 
residents had LTBI. In comparison, our method leads to an estimated prevalence of 18.0% in overseas-
born Australians in 2006. A separate UK study among all migrants attending three UK medical centres 
(2008-2010) found 144/740 (20%) born in the Indian subcontinent  ?A? ? ?ǇĞĂƌƐ ?ǁĞƌĞ/'ZƉŽƐŝƚŝǀĞ ?6 and 
on equivalent subsets from the Australian migration data in 2006 (by country of birth, year of arrival and 
age), we estimated 20.9% to have LTBI. Overall, then, our estimates appear concordant with existing 
data from testing in migrant populations. 
Some uncertainty must also be acknowledged due to the small amount of missing census data. Despite 
this, census data remains a good source of comprehensive data, and post-enumeration survey data 
suggested that the countries of birth of census non-respondents did not differ greatly from the census 
respondents,
9
 meaning that although we have probably slightly underestimated the numbers with LTBI, 
the proportions presented should be less affected.   
Our method also made the assumption that, once infected, individuals remained infected for life, and so 
provides information about the risk of an individual having ever been infected. No allowance was made 
for the possibility that individuals may clear LTBI over time since infection, for which there is evidence.
37 
38
 Furthermore, in some settings LTBI screening and treatment may already be systematically provided 
to certain migrant groups and LTBI estimates may need to account for this. This is not the case in 
Australia, where overseas visa applicants identified has having a CXR revealing old, inactive TB may be 
offered LTBI screening and treatment as part of their health follow-up,
39
 however the impact of these 
practices on overall LTBI prevalence is likely to be small, due to the small number of migrants referred to 
the program.
40
  
Our method combines global TB infection estimates with migration data to provide useful insights into 
the prevalence of latent TB in our low-incidence setting. The method could be easily repeated in any 
setting with reliable census data. Resulting quantitative estimates can assist in developing rational 
strategies for LTBI screening, which allow for opportunities to promote the long-term health of 
overseas-born residents and contribute towards the ultimate goal of global TB elimination. 
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Table 1 Estimated LTBI among Australian residents in 2016, with country-specific results from the ten countries of birth  1 
contributing the greatest numbers with LTBI. 2 
Country of 
birth 
Percentage 
of 
Australian 
population 
(%) 
Median 
number, in 
thousands, 
estimated 
to have LTBI 
in Australia  
(IQR) 
Median 
age of 
resident 
with 
LTBI 
(years) 
Median 
years since 
arrival of 
those 
estimated 
to have 
LTBI 
Median 
percentage 
of all LTBI in 
Australia 
(%) 
Median percentage with LTBI by age group (IQR) 
0-14  
years 
15-34  
years 
35-64  
years 
ш ? ? 
years 
All 
China 
2.3 113 53 12 11.8 1.5 9.1 29.2 65.6 21.3 
 
(89-140)  
 
 
(1.4-
1.6) 
(8.5-
9.8) 
(22.3-
38.4) 
(43.2-
85.8) 
(16.8-
26.6) 
India 
2.1 115 36 8 12.1 2.9 22.9 31.5 45.9 26.0 
 (108-124)  
 
 
(2.7-
3.1) 
(21.6-
24.3) 
(29.3-
34.5) 
(38.2-
54.9) 
(24.4-
28.0) 
Philippines 
1.1 101 47 12 10.6 6.8 28.1 55.3 80.2 44.7 
 
(85-117)  
 
 
(6.3-
7.3) 
(26.5-
30.0) 
(45.8-
66.1) 
(57.4-
96.0) 
(37.9-
51.8) 
Vietnam 
1.0 96 55 27 10.0 3.3 18.9 49.9 91.0 45.5 
 
(61-125)  
 
 
(3.0-
3.6) 
(17.0-
21.4) 
(29.8-
70.0) 
(57.8-
99.9) 
(29.1-
59.5) 
South Africa 
0.7 37 45 9 3.8 8.2 16.8 27.4 25.8 22.9 
 
(30-52)  
 
 
(7.6-
9.0) 
(15.9-
18.3) 
(21.5-
39.1) 
(16.1-
56.9) 
(18.6-
32.4) 
Indonesia 
0.3 32 41 13 3.3 7.9 34.4 53.1 67.5 44.6 
 
(30-33)  
 
 
(7.4-
8.4) 
(33.1-
35.6) 
(50.9-
55.5) 
(56.4-
79.7) 
(42.7-
46.6) 
Cambodia 
0.2 24 49 25 2.6 11.5 50.0 85.6 100.0 76.0 
 
(20-26)  
 
 
(10.8-
12.2) 
(46.2-
54.6) 
(66.0-
93.3) 
(91.4-
100.0) 
(62.6-
82.0) 
South Korea  
0.5 25 49 14 2.6 1.4 9.1 39.6 92.6 26.7 
 
(23-27)  
 
 
(1.3-
1.6) 
(8.5-
9.9) 
(36.0-
43.2) 
(84.9-
97.8) 
(24.5-
28.5) 
Pakistan 
0.3 17 35 5 1.8 4.1 24.2 41.5 68.7 27.9 
 
(15-18)  
 
 
(3.8-
4.4) 
(23.0-
25.6) 
(36.0-
48.5) 
(54.3-
79.6) 
(25.4-
30.9) 
Myanmar 
0.2 16 45 8 1.7 9.4 34.3 60.4 87.3 51.1 
 
(13-18)  
 
 
(8.5-
10.2) 
(32.0-
36.6) 
(49.4-
75.7) 
(61.2-
98.4) 
(42.6-
59.1) 
Other 
countries 
19.6 413 56 25 39.8 0.9 5.4 10.4 16.8 10.4 
 
(378-456)  
 
 
(0.9-
1.0) 
(5.3-
5.6) 
(9.7-
11.2) 
(14.6-
20.1) 
(9.5-
11.4) 
All overseas-
born 
28.3 998 49 15 93.2 2.1 11.3 20.1 22.9 17.1 
 
(943-1058)  
 
 
(2.0-
2.1) 
(11.1-
11.6) 
(18.7-
21.3) 
(20.6-
25.8) 
(16.2-
18.1) 
Australian-
born 
71.7 65 54 - 6.8 0.1 0.3 0.6 0.9 0.4 
 
(48-112) 
 
 
 
(0.1-
0.1) 
(0.2-
0.3) 
(0.4-
0.9) (0.5-2.3) 
(0.3-
0.7) 
  
Figure 1 Number and percentage of Australians estimated to have LTBI by census year. Vertical lines represent data points 
that are no more than 1.5 times the interquartile range from the box. 
 
 Figure 2 Estimated number and percentage estimated to have LTBI by age group and census year. Vertical lines represent 
data points that are no more than 1.5 times the interquartile range from the box. 
 Figure 3 Number arriving by year of Australian residents in 2016 who were born in countries with a high burden of TB (as 
defined by the WHO 2017 Global TB Report
19
). Birth countries with fewer than 10,000 residents excluded. 
 
 
  
 
Figure 4 Estimated number of overseas-born residents in Australia for the four most common countries of birth, by age and 
LTBI status, at time of migration and as at the 2016 census. 
  
Appendices 
The probabilities of infection in the Australian-born (pa) and in the overseas-born (po) are given by: ݌௔ ൌ  ? െ݁ିுೌ ݌௢ ൌ  ? െ݁ିு೚  
ܪ௔ ൌ   ? ?ൗ ܨܱܫ௕௔ ൅ ෍ ܨܱܫ௜௔௙௜ୀ௕ାଵ  
ܪ௢ ൌ   ? ?ൗ ܨܱܫ௕௦ ൅ ෍ ܨܱܫ௜௦௠ିଵ௜ୀ௕ାଵ ൅  ? ?ൗ ܨܱܫ௠௦ ൅  ? ?ൗ ܨܱܫ௠௔ ൅ ෍ ܨܱܫ௜௔௙௜ୀ௠ାଵ  
Where FOI indicates the force of infection that an Australian-born (a) or overseas-born (o) person was 
exposed to in a specific year and country, and H indicates the cumulative force of infection. The 
subscripts a, b, m, s and f refer to Australia, birth year, migration year, source country and final year of 
calculation respectively, and are applied to forces of infection in specific years and countries. 
a)  
 
b)
 
Figure S1 Estimated percentage of residents with LTBI in Australia over time by a) region of Australia and 
b) local government area in Greater Melbourne.  
